Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA +4.55% EV-to-OCF is -50.47 as of Aug. 10, 2026. The stock has 6 warning signs investors should review. Among 1,405 Biotechnology companies, Emmaus Life Sciences ranks better than 92.31% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Emmaus Life Sciences's Enterprise Value is $32.00 Mil.
Emmaus Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.63 Mil. Therefore, Emmaus Life Sciences's EV-to-OCF for today is -50.47.
The historical rank and industry rank for Emmaus Life Sciences's EV-to-OCF or its related term are showing as below:
EMMA'
s EV-to-OCF Range Over the Past 10 Years
Min: -2856.93 Med: -15.18 Max: 429.71
Current: -50.47
During the past 13 years, the highest EV-to-OCF of Emmaus Life Sciences was 429.71. The lowest was -2856.93. And the median was -15.18.
EMMA's EV-to-OCF is ranked better than 92.31% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs EMMA: -50.47
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Emmaus Life Sciences (OTCPK:EMMA) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Emmaus Life Sciences's PE Ratio (TTM) for today is calculated as:
Emmaus Life Sciences's share price for today is $0.0115.
Emmaus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Emmaus Life Sciences EV-to-OCF Related Terms
Emmaus Life Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's EV-to-OCF falls into.
Emmaus Life Sciences's current Enterprise Value is $32.00 Mil.
Emmaus Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a EV-to-OCF of -50.47 as of Aug. 10, 2026. According to the industry distribution chart, Emmaus Life Sciences ranks #108 out of 1405 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Emmaus Life Sciences' EV-to-OCF too high?
Emmaus Life Sciences' current EV-to-OCF is -50.47. Based on the distribution chart, Emmaus Life Sciences ranks #108 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' EV-to-OCF compare to AGTX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #108 out of 1405 companies for EV-to-OCF. This places Emmaus Life Sciences in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Emmaus Life Sciences's current EV-to-OCF is -50.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 15% above its estimated fair value. The current EV-to-OCF is -50.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current EV-to-OCF is -50.47 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
